Abstract: Compositions containing vitamin D compounds in a suitable carrier and methods employing such compositions are disclosed for cosmetic uses in the treatment of various skin conditions such as lack of adequate skin firmness, wrinkles, lack of dermal hydration and insufficient sebum secretion. Various formulations of the compositions including creams, lotions and ointments are disclosed for use topically, orally or parenterally in accordance with this invention.

Abstract: A kit containing benzeneacetonitrile and calcium or dihydropyridine and calcium hypertensive mammals may be treated to lower mean blood pressure by administering a calcium channel blocking agent together with one or both of a calcium supplement and Vitamin D. The hypotensive effect of this combination is synergistic and the dose response is more predictable than the administration of any of these agents singly.

Abstract: Disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric-oxide or related redox species, in a concentration effective to effect neuroprotection. Also disclosed is a method for decreasing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitroso-compound that generates nitric oxide (or a related redox species such as NO.sup.31 or NO.sup.+ equivalent), or a physiologically concentration effective to cause such neuroprotection.

Abstract: A new use of, and method of treatment of atherosclerosis using, a compound selected from the group consisting essentially of compounds of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;R.sub.2 is hydrogen, lower alkyl of up to 6 carbon atoms or arylalkyl selected from benzyl, phenylethyl and phenylpropyl;R.sub.3 is hydrogen or lower alkyl of up to 6 carbon atoms;R.sub.4 is hydrogen or lower alkyl of up to 6 carbon atoms, or when X is oxygen, R.sub.4 together with R.sub.5 can represent --CH.sub.2 --O--;X is a valency bond, --CH.sub.2, oxygen or sulfur;Ar is selected from phenyl, naphthyl, indanyl and tetrahydronaphthyl;R.sub.5 and R.sub.6 are individually selected from hydrogen, fluorine, chlorine, bromine, hydroxyl, lower alkyl of up to 6 carbon atoms, a --CONH.sub.

Abstract: Methods for the treatment of a human or lower animal subject having an H. pylori-mediated upper gastrointestinal disorder comprising administering to said subject a safe and effective amount of a diphenyl ether phosphate ester of the following formula: ##STR1## wherein n is an integer from 0 to 3, or a pharmaceutically-acceptable salt thereof.

Abstract: The use of biomasses obtained in the fermentative production of lipase inhibitors, especially lipstatin, for the preparation of foodstuffs, feedstuffs, food additives, feed additives, feed supplements, medicinal feed premixes or medicaments for oral administration, are described.

Abstract: Use of Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo [1,2-6]pyridazin-2-yl]carbamate or pharmaceutically acceptable salt to treat lymphocytic leukemia is disclosed.

Abstract: The present invention is directed to a method for treating symptoms associated with vascular headaches. The method comprises administering to an individual exhibiting symptoms associated with vascular headache symptomatology a therapeutically effective amount of a combination of calcium and vitamin D.

Abstract: The present invention relates to the use of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acids and analogs thereof in antagonizing the binding of angiotensin II to AT.sub.2 receptors to treat memory loss.

Abstract: (Endo)-N-[[[8-azabicyclo[3.2.1]octan-3-yl]amino]carbonyl]-2-(cyclopropylmet hyloxy)benzamide and pharmaceutically acceptable salts thereof possess 5-HT.sub.3 antagonistic activity and are useful in the treatment of neuro-psychiatric disorders (e.g. anxiety), gastro-intestinal disorders and migraine.

Abstract: Propargylamine derivatives having the general formula: ##STR1## wherein R is a hydrogen atom, an unsubstituted phenyl group or a phenyl group substituted with halogen, trifluoromethyl, loweralkoxy, nitro, cyano, amido or N,N-diloweralkylamido, R.sub.1, R.sub.2 or R.sub.3 are the same or different and each represent a hydrogen atom or a loweralkyl group, R.sub.4 is a hydrogen atom or a loweralkyl, benzyl, phenethyl or furyl group, or R.sub.3 and R.sub.4 together with the nitrogen atom to which they are attached form a piperidinyl group, and their pharmaceutically acceptable acid addition salts, have been found to be useful in the treatment of anxiety, psychotic states and aggressive behavior in affected animals.

Abstract: A method of inhibiting demyelinating or dysmyelinating diseases or their symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.

Abstract: This invention relates to the use of a compound of formula ##STR1## wherein X is --CH.sub.2 -- or ##STR2## R.sub.1 is H, C.sub.1-5 -alkyl or benzyl, which can be substituted of unsubstituted; R.sub.2 is H, C.sub.1-4 -alkyl, C.sub.1-4 -alkenyl, OH, or C.sub.1-3 -alkoxy; R.sub.3 is H, CH.sub.3, C.sub.2 CH.sub.3, OCH.sub.3, or Hal; R.sub.4 H, CH.sub.3, C.sub.2 CH.sub.3, OCH.sub.3, or Hal, and Hal is halogen, provided that when R.sub.2 is OH or C.sub.1-3 -alkoxy then X cannot be CO or a non-toxic pharmaceutically acceptable salt thereof for the use in the treatment of age related memory impairment or cognitive disorders, particularly Alzheimer's Disease.

Abstract: A prophylactic pretreatment for nerve gas and pesticide poisons which can be administered orally and which comprises the following agents, in combination: a. Pyridostigmine (pyridostigmine bromide) b. Diazepam c. N-methyl-4-pipyridinyl phenylcyclopentanecarboxylateThese agents may be administered in the form of a capsule which contains, for example, tablets, one a normal release dosage form and one or two in a slow release dosage form.

Abstract: Pharmaceutical compositions comprising compounds of the formula: R.sup.2 C{CH.sub.2 O(CH.sub.2).sub.n CO[NR.sup.3 CHR(CH.sub.2).sub.m CO].sub.q NOHR.sup.1 }.sub.3, wherein R is hydrogen, alkyl optionally substituted by OR.sup.5, SR.sup.5, NR.sup.5 R.sup.6, COR.sup.6, COOR.sup.6, CONR.sup.5 R.sup.6, --NHC(NR.sup.5 R.sup.6).dbd.NR.sup.7, aryl, aralkyl or heteroaryl; R.sup.1, R.sup.2 and R.sup.3 are independently selected from the group consisting of hydrogen, alkyl, aralkyl, aryl, COOR.sup.4, CONHR.sup.4 and CONR.sup.4 R.sup.4 ; R.sup.2 may additionally be alkyl substituted by alkoxy, alkenyloxy or by a group --O--(CH.sub.2).sub.p --COOX or --O--(CH.sub.2).sub.p --CONHX, wherein p is an integer from 1 to 10 and X is alkyl, aralkyl, aryl or heteroaryl; R.sup.4, R.sup.5 and R.sup.6 are hydrogen, alkyl, aralkyl, aryl or heteroaryl; n is 1 or 2, m is 0, 1 or 2 and q is 0 or 1, and when m is 0, the moiety --NR.sup.

Abstract: A method for the photodynamic therapy of rheumatoid arthritis of mammals, which agent comprises at least one member of fluorescent compounds selected from the group consisting of tetrapyrrole carboxylic acids having at least one carboxyl group, corresponding di- or tetrahydrotetrapyrrole carboxylic acids, and mono-, di- or polyamides of the tetrapyrrole carboxylic acids with amino-mono- or dicarboxylic acids and their salts.

Abstract: This invention encompasses pharmaceutical compositions in the dietary supplement for treating or preventing fatty infiltration, the first stage of cirrhosis of the liver comprising and administering of not less than 1500 mg of betaine per kg of body weight per day. Dietary supplementation of betaine was shown to completely protect against liver fatty infiltration in rats exposed to prolonged ethanol intake as well as carbon tetrachloride. Hepatic levels of SAM were also elevated, which suggests the mechanism for the protection of the liver.

Abstract: The use of a compound possessing functional antagonist properties at the NMDA receptor complex through a specific action at the associated strychnine-insensitive glycine site to improve cognition in normal humans and to treat cognitive deficits resulting from chronic neuronal degeneration, acute brain injury, hypoxia, or other neurological disorders is provided. The compounds possessing functional antagonist properties comprise 1-aminocyclopropanecarboxylic acid, and its pharmaceutically acceptable esters, salts, and acid addition salts or 7-chlorokynurenic acid, and its pharmaceutically acceptable esters, amides, salts, ethers, and acid addition salts.

Abstract: Methods for treatment of humans and other animals with dimercaptosuccinic acid (DMSA). DMSA is administered to reduce levels of silicon in blood and tissue, reduce blood pressure, improve kidney function, prevent or retard the progression of chronic renal failure, treat the accumulation of silicon in advanced kidney disease, decrease accumulation of reactive oxygen metabolites, increase superoxide dismutase activity, and/or prevent the onset or improve the current status of senile dementia or Alzheimer's disease.

Abstract: A method for promoting weight control by treating a subject with a therapeutic amount of one of the .DELTA.5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones. .DELTA.5-Androstenes providing the desired biological activities include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one.DELTA.5-Androstene-3.beta.-ol-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol.DELTA.5-Androstene-3.beta.,17.beta.-diol-7-one.DELTA.5-Androstene-3.beta.-acetoxy-7,16,17-trione.DELTA.5-Androstene-3.beta.,16.alpha.-dihydroxy-7,17-dione.DELTA.5-Androstene-3.alpha.-propionoxy-16.beta.-acetoxy-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol-16-one.DELTA.5-Androstene-3.beta.,17.beta.-diol-7,16-dione.DELTA.5-Androstene-3.beta.,16.alpha.,17.beta.-triol-7-one.